AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Olaparib Extends Survival in BRCA/ATM Mutated Prostate Cancer

Significant survival benefit observed in Cohort A despite 67% crossover from control arm masking the true effect size

Design PROfound Phase 3 Trial Population mCRPC with HRR gene alterations (progressed on prior NHA) N 387 Duration Median follow-up ~21 months Comparator Physician's choice (Enzalutamide or Abiraterone) Year 2020
Drag

Key Performance Indicators

PRIMARY
Median OS (Cohort A)
19.1 mo
vs 14.7 mo Control
4.4 month gain
PRIMARY
Hazard Ratio (Cohort A)
0.69
95% CI: 0.50–0.97
31% risk reduction
Crossover-Adjusted HR
0.42
Sensitivity Analysis
58% risk reduction (est.)
Control Crossover Rate
67%
86 of 131 patients
High contamination
Drag
01

Olaparib Consistently Extends Median Overall Survival

Median overall survival was longer in the Olaparib arm across all cohorts, with the most distinct separation in the primary analysis population (Cohort A).

Cohort A (BRCA1/2, ATM)Cohort B (Other Genes)Overall Population05101520OlaparibControl
Drag
02

Crossover Heavily Dilutes the Observed Survival Benefit

When adjusting for the 67% of control patients who crossed over to receive Olaparib, the Hazard Ratio improves dramatically, suggesting the ITT analysis underestimates efficacy.

Cohort A (ITT)Cohort A (Adjusted)Overall Pop (ITT)Overall Pop (Adjusted)200m400m600m800m11.20.690.420.790.55
Drag
03

Survival Benefit is Driven by BRCA Mutations

Exploratory gene-level analysis reveals that BRCA1 and BRCA2 alterations drive the survival advantage, while non-BRCA alterations show no clear benefit.

HR = 1.0BRCA1 AlterationBRCA2 AlterationNon-BRCA Genes0.000.501.001.500.420.590.95
Drag
04

Hematologic Toxicity is the Primary Safety Trade-off

Olaparib is associated with significantly higher rates of anemia and nausea compared to the hormonal control arm.

AnemiaNauseaFatigue/AstheniaDecreased Appetite40200204050.0−15.043.0−21.042.0−33.031.0−18.0OlaparibControl
Drag
05

Benefit Persists Through Subsequent Therapies (PFS2)

Time to second progression (PFS2) was significantly longer with Olaparib, indicating the treatment effect is durable even after patients progress and switch therapies.

Cohort ACohort BOverall Population051015OlaparibControl
Drag

Editorial Conclusion

“Olaparib provides a statistically significant overall survival benefit in mCRPC patients with BRCA1/2 or ATM alterations, reducing the risk of death by 31% in the ITT analysis.”
The survival benefit increases to a 58% risk reduction when adjusting for the high rate (67%) of control patients crossing over to Olaparib.
Efficacy is primarily driven by BRCA1 and BRCA2 alterations, with less clear benefit in other HRR genes.
Safety profile is consistent with known PARP inhibitor effects, primarily anemia and nausea.
Clinical Implication
These results support the use of Olaparib in patients with BRCA1/2 or ATM mutated mCRPC who have progressed on prior hormonal agents, highlighting the importance of genomic testing.
Drag

Reference Sources & Abbreviations

Abbreviations
HR Hazard Ratio CI Confidence Interval OS Overall Survival PFS2 Progression-free survival 2 ITT Intention to Treat
Source
N Engl J Med 2020;383:2345-57
DOI: 10.1056/NEJMoa2022485
Limitations
High crossover rate complicates OS interpretation
Study not powered for individual gene subgroup analyses
Investigator-assessed endpoints subject to potential bias
Drag
New container
Drag
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

AI edit element

Describe the change you want. Optional: attach an image.
No image attached
👀 View Mode